Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Granisetron (ausschl. Dafo. PFT), ATC A04AA02 f. d. Z. 01.08.2026 - 31.07.2028 (zzgl. V.-Option 1x12 Monate)

DAK-GesundheitHamburg, GermanyEUR 1 / ~EUR 11082 days leftopen

Inscrivez-vous pour sauvegarder Documents (1)

Opportunity Score

Confidence: 70%

Complexity: low

1082 days

Deadline

supplies

Contract

Deep Portfolio Analysis

Company fit score
Missing certificates
Eligibility blockers
Bid / No-Bid recommendation

Create account for AI analysis

AI Analysis Summary

Moderate opportunity

Non-exclusive discount agreement (Rabattvereinbarung) for the active substance Granisetron (excluding PFT form), ATC A04AA02, under §130a Abs. 8 SGB V. Open to all pharmaceutical companies with rolling enrollment. Contract period: 01.08.2026 – 31.07.2028 with a 1-year extension option. No competitive selection; all qualifying companies can join. Estimated value is symbolic (1 EUR). Submission via email to [email protected].

Strengths

Documents available

Open procedure

Low complexity

Key Requirements

Submit offer letter (Angebotsschreiben) accepting the contract terms.
Return the signed contract with company stamp/name in the designated place.
Complete Annexes 1 and 2, listing the specific medicines to be covered.

Buyer

Name

DAK-Gesundheit

Location

Hamburg, DEU

[email protected]

Website

www.dak.de

Identifier

DE48698890

Lots (1)

#LOT-0001Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Granisetron (ausschl. Dafo. PFT), ATC A04AA02 f. d. Z. 01.08.2026 - 31.07.2028 (zzgl. V.-Option 1x12 Monate)

Non-exclusive discount agreement for Granisetron (PFT excluded). Open to all pharmaceutical companies on equal terms. Contract automatically ends if an exclusive contract is concluded later.

EUR 133600000DEU